Turnstone Biologics Revenue and Competitors

Ottawa, ON CAN

Location

$132.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Turnstone Biologics's estimated annual revenue is currently $19.7M per year.(i)
  • Turnstone Biologics received $41.4M in venture funding in November 2016.
  • Turnstone Biologics's estimated revenue per employee is $155,000
  • Turnstone Biologics's total funding is $132.7M.

Employee Data

  • Turnstone Biologics has 127 Employees.(i)
  • Turnstone Biologics grew their employee count by -5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M21-51%$39.4MN/A
#2
$1M13-81%$23.8MN/A
#3
$82.3M5313%N/AN/A
#4
$2.6M1713%N/AN/A
#5
$7.8M50-68%N/AN/A
#6
$17.8M115-6%N/AN/A
#7
$0.9M12-33%N/AN/A
#8
$13.6M88-20%$86MN/A
#9
$22.6M146-18%N/AN/A
#10
$0.5M60%N/AN/A
Add Company

Turnstone Biologics is a privately-held immuno-oncology company dedicated to delivering breakthrough viral immunotherapies to improve survival for patients with cancer. With an experienced leadership team passionate about helping people with cancer, comprehensive capabilities in immuno-oncology discovery, basic research, translation, clinical development, manufacturing and commercialization, Turnstone Biologics is the sole company developing viral immunotherapies to drive benefit through simultaneous generation of a targeted immune response and modulation of the tumor environment. The company's engineered oncolytic Maraba virus, known as MG1, is the first therapeutic 2-in-1 approach to combine an oncolytic virus and an antigen-specific cancer vaccine. With its unprecedented dual-mechanism approach, MG1 kills cancer cells both locally and at metastatic sites throughout the body, and generates a durable immune response resulting in long-term memory to prevent recurrence. The company has developed a robust pipeline of new medicines for multiple solid tumors. The most advanced program, called Ad-MG1-MAGEA3, is being evaluated in patients with non-small cell lung cancer (NSCLC), breast cancer and esophageal cancer in two clinical trials. A second Maraba-based therapy designed for patients with human papillomavirus (HPV) positive tumors and multiple other viral immunotherapies are in development. Turnstone Biologics has entered into a research, option and license agreement with AbbVie for its next-generation viral immunotherapies. In 2017, the company was selected as a Fierce 15 winner - a designation signifying that it is considered one of the up-and-coming biotech companies expected to make big waves in the industry. Based in Ottawa, Ontario, and New York, Turnstone Biologics has raised approximately $50 million in venture capital financing since inception.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

$132.7M

Total Funding

127

Number of Employees

$19.7M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Turnstone Biologics News

2022-04-17 - Health Hires: Ichnos Sciences, Turnstone Biologics

and Turnstone Biologics Corp. have named new general counsel recently, highlighting Law360's latest roundup of personnel moves in health care...

2022-04-17 - Turnstone Biologics Announces TIL Therapy Research ...

Turnstone Biologics Corp., a clinical-stage biotechnology company, is developing new medicines to treat and cure solid tumors by pioneering...

2022-04-13 - Turnstone Biologics Announces Executive Leadership ...

Turnstone Biologics Announces Executive Leadership Appointments. Additions of Venkat Ramanan, Ph.D., as Chief Financial Officer and P. Joseph...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$41.9M12726%N/A
#2
$26M127-2%N/A
#3
$37.4M129-3%N/A
#4
$35M1298%N/A
#5
$13M1304%N/A

Turnstone Biologics Funding

DateAmountRoundLead InvestorsReference
2015-10-29$UndisclosedAVersant VenturesArticle
2016-11-03$41.4MBOrbiMedArticle